A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease
About This Grant
Abstract Alcohol use disorder (AUD) is a devastating disease with significant morbidity and mortality, particularly due to alcohol-associated liver disease (ALD). Early intervention and optimal medication adherence to medications for AUD (MAUD) can decrease alcohol use and prevent the progression of liver damage. Yet, adherence to MAUD, especially acamprosate - the preferred medication for AUD in individuals with ALD - remains suboptimal. This K23 proposal seeks to leverage an innovative digital pill system (DPS) that directly measures acamprosate ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention. The DPS will collect real-time adherence data to contextualize and personalize smartphone-delivered adherence support, potentially revolutionizing how adherence is managed in high-risk AUD populations. To achieve this goal, we will 1) develop a user-centered adherence intervention paired with a DPS (AcamproSync) to informed tailored support for participants with ALD and AUD taking acamprosate; 2) test the feasibility and acceptability of AcamproSync through a pilot randomized controlled trial in N=50 individuals with AUD and ALD prescribed acamprosate compared to treatment as usual; and 3) assess user experience and barriers to the implementation of AcamproSync, guided by the Reach-Effectiveness-Adoption, Implementation, and Maintenance (RE-AIM) framework. By addressing key gaps in adherence to MAUD, this project has the potential to significantly impact AUD treatment outcomes. This study will also provide foundational data for the development of a scalable digital health-based intervention to improve adherence that has trans-NIH applicability to other high priority health issues.
Grant Summary
A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease is a NIAAA - National Institute on Alcohol Abuse and Alcoholism grant providing up to $193K for university, nonprofit, healthcare org. Applications are due 2030-08-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $193K
2030-08-31
- 1Confirm your organization is eligible for A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease from NIAAA - National Institute on Alcohol Abuse and Alcoholism, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAAA - National Institute on Alcohol Abuse and Alcoholism before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAAA - National Institute on Alcohol Abuse and Alcoholism's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease: Frequently Asked Questions
Who is eligible for the A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease?
A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease is offered by NIAAA - National Institute on Alcohol Abuse and Alcoholism and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease provide?
A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease provides up to $193K per award from NIAAA - National Institute on Alcohol Abuse and Alcoholism. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease deadline?
Applications for A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease are due 2030-08-31 (open). Because deadlines can change, verify the date with the funder, NIAAA - National Institute on Alcohol Abuse and Alcoholism, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease?
To apply for A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAAA - National Institute on Alcohol Abuse and Alcoholism.